Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS

Key Points

• Royalty Pharma beat quarterly earnings expectations, reporting $1.30 EPS versus the $1.22 consensus, though revenue of $631 million fell short of estimates.
• Management highlighted a strong quarter with portfolio receipts up 10% and royalty receipts up 13%, and said it raised 2026 guidance while increasing the dividend by 7%.
• The company is expanding its R&D co-funding strategy with major deals such as J&J and Teva, while also citing key portfolio catalysts and solid financial flexibility, including a Fitch upgrade to BBB.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08, Zacks reports. The company had revenue of $631.00 million for the quarter, compared to analysts' expectations of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.49%.

Here are the key takeaways from Royalty Pharma's conference call:

• Royalty Pharma reported a strong Q1 with portfolio receipts up 10% and royalty receipts up 13%, delivered ~14% ROIC and ~20% ROIE, repurchased 1M shares for $50M, raised the 2026 guidance, and increased the dividend by 7%.
• The company is aggressively scaling R&D co-funding with Global Biopharma — announcing J&J and Teva deals totaling ~$1B this quarter — positioning to capture demand from an industry with >$1T projected R&D spend over five years.
• Material portfolio catalysts include Revolution Medicines’ daraxonrasib Phase III that nearly doubled overall survival in 2L pancreatic cancer, FDA approval of Denali’s Avlayah, and acquisition of a royalty on Ziihera (management cites >$2B peak sales potential and low‑double digit unlevered IRR).
• Financial flexibility remains strong with $586M cash, ~$722M portfolio cash flow in Q1, $9.2B of long‑dated investment‑grade debt (12‑yr avg duration), an undrawn $1.8B revolver and a recent Fitch upgrade to BBB, giving ~ $4B+ access to capital.
• Near‑term risks include lower expected milestones (from $128M in 2025 to ~$60M in 2026), headwinds from Promacta LOE, potential US biosimilar TYSABRI and IRA impacts, and an arbitration with Vertex now expected to resolve around mid‑2027.

Royalty Pharma Stock Up 1.2%

NASDAQ RPRX traded up $0.59 on Friday, hitting $50.79. 3,764,589 shares of the company were exchanged, compared to its average volume of 3,543,437. The company has a market cap of $29.30 billion, a PE ratio of 34.55, a PEG ratio of 3.24 and a beta of 0.40. Royalty Pharma has a 12 month low of $32.15 and a 12 month high of $51.65. The stock has a fifty day moving average of $47.62 and a 200-day moving average of $42.75. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma's dividend payout ratio is presently 63.95%.

Insider Activity

In other news, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 139,164 shares of company stock worth $6,624,902. 18.84% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Royalty Pharma

A number of hedge funds have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its position in shares of Royalty Pharma by 66.4% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company's stock worth $43,000 after purchasing an additional 446 shares during the period. Larson Financial Group LLC grew its position in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 306 shares during the period. Smartleaf Asset Management LLC increased its stake in Royalty Pharma by 59.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,405 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 524 shares in the last quarter. Transamerica Financial Advisors LLC raised its holdings in Royalty Pharma by 10.7% during the fourth quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company's stock worth $199,000 after buying an additional 498 shares during the last quarter. Finally, Hilltop Holdings Inc. bought a new position in shares of Royalty Pharma in the third quarter valued at $205,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on RPRX shares. Morgan Stanley upped their price target on Royalty Pharma from $61.00 to $63.00 and gave the company an "overweight" rating in a research report on Friday, April 10th. JPMorgan Chase & Co. raised their price objective on Royalty Pharma from $50.00 to $58.00 and gave the stock an "overweight" rating in a research report on Thursday. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Citigroup upped their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a "buy" rating in a report on Thursday. Finally, Wall Street Zen lowered shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 14th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $53.71.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.